Clinical Program Risk Radar
Track public delay, stagnation, termination, recruitment burden, and missing-results signals across clinical assets using ClinicalTrials.gov and snapshot history.
Built from ClinicalTrials.gov registry text and snapshot history. Signals reflect what is publicly observable — not clinical outcome predictions, compliance determinations, or assessments of sponsor financial health.
Which assets or sponsors deserve closer review based on public signals?
This module surfaces public registry signals — delay, stagnation, termination, long recruitment, missing results — that may warrant deeper diligence. It does not predict trial failure. It helps teams identify which programs to look at more carefully, sooner.
Target users
- Biotech investors monitoring portfolio and competitive assets
- Pharma competitive-intelligence teams tracking clinical pipelines
- BD diligence teams evaluating potential in-licensing candidates
- CRO feasibility teams assessing program health before partnership
- Strategic consultants tracking sponsor-level public risk patterns
- Portfolio-monitoring teams running monthly watchlist review
Public risk signals detected
- Terminated, withdrawn, or suspended trials
- Unknown or stale trial status
- Long-running recruitment periods
- Primary completion dates that appear stale
- Completed trials with no public results found
- Assets with multiple stalled or stopped trials
- Sponsors with repeated public trial-risk signals
- Patent activity continuing after apparent trial stall
This module does not predict trial failure. It surfaces public risk signals that may require closer diligence. Every output is designed for expert review, not automated action.
How teams use this module
- Monitor a watchlist of oncology Phase 2 assets for registry status changes monthly
- Track completion-date and status changes to identify staleness patterns early
- Identify long-recruiting trials that may signal enrollment difficulty
- Compare sponsor-level public risk signals across a competitive landscape
- Detect multi-trial stall patterns around a single asset or program
- Generate custom clinical-program risk scans for BD diligence or portfolio review
Oncology Phase 2 Small/Mid-Cap Sponsor Edition
Track registry stop signals, timeline staleness, long recruitment, results-not-found signals, and multi-trial patterns across oncology Phase 2 assets.
- Asset-program pages, sponsor pages, and trial pages
- Monthly snapshot archive rows from day one
- Neutral labels built around public signals, not predictions
- Optional patent appendix as context only
Receive Clinical Program Updates by Email
Tell us which assets, sponsors, or indications you want monitored. We use this for email updates, monthly monitoring requests, and CSV delivery preferences.